海通证券股份有限公司 关于成都普瑞眼科医院股份有限公司 2023 年度募集资金存放与使用情况之专项核查意见 海通证券股份有限公司（以下简称"海通证券"或"保荐机构"）作为成都 普瑞眼科医院股份有限公司（以下简称"普瑞眼科"或"公司"）首次公开发行 股票并在创业板上市持续督导保荐机构，根据《证券发行上市保荐业务管理办法》 《深圳证券交易所创业板股票上市规则》《上市公司监管指引第 2 号——上市公 司募集资金管理和使用的监管要求》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作（2023 年 12 月修订）》（深证上〔2023〕1146 号）等有关规定，对《成都普瑞眼科医院股份有限公司 2023 年度募集资金存放 与使用情况的专项报告》进行了审慎核查，核查情况及核查意见如下： 一、募集资金基本情况 (一) 实际募集资金金额和资金到账时间 根据中国证券监督管理委员会《关于同意成都普瑞眼科医院股份有限公司首 次公开发行股票注册的批复》（证监许可〔2022〕587 号），首次向社会公众公 开发行人民币普通股（A 股）股票 3,740.4762 万股，发行价为每股人民币 33.65 元，共计募集资 ...

Financial Performance - The company reported a net profit increase of 92.44% during the reporting period, primarily due to significant revenue growth [25]. - Operating cash inflow increased by 53.42%, attributed to the substantial rise in annual revenue [24]. - The company achieved operating revenue of CNY 2,717,873,370.90 in 2023, representing a year-on-year growth of 57.50% [37]. - Net profit attributable to shareholders reached CNY 267,913,456.76, an increase of 1202.56% compared to the same period in 2022 [37]. - The total revenue for 2023 reached CNY 2,717,873,370.90, representing a 57.50% increase compared to CNY 1,725,640,393.39 in 2022 [77]. - The net profit after deducting non-recurring gains and losses was CNY 197,813,058.48, up 967.07% from CNY 18,538,023.18 in 2022 [77]. - Basic and diluted earnings per share both stood at CNY 1.79, a remarkable increase of 1,018.75% from CNY 0.16 in 2022 [77]. - The weighted average return on net assets was 12.21%, significantly higher than 1.36% in the previous year [77]. Revenue Breakdown - The refractive project generated revenue of ¥1,296,067,407.11, which is 47.69% of total revenue, showing a growth of 33.52% year-on-year [114]. - The cataract project saw a significant revenue increase of 137.96%, reaching ¥593,711,660.50, which is 21.84% of total revenue [114]. - The optical project contributed ¥396,758,777.65, representing 14.60% of total revenue, with a year-on-year growth of 52.65% [116]. - Revenue from the medical sector amounted to ¥2,705,084,920.09, accounting for 99.53% of total revenue, with a growth of 57.77% compared to the previous year [114]. Investment and Acquisitions - The company completed the acquisition of Dongguan Guangming Eye Hospital for an investment amount of CNY 430,607,637.97, acquiring an 80% stake [52]. - The expected return from the investment in Dongguan Guangming Eye Hospital is CNY 520,000,000.00, with a reported investment gain of CNY 523,123,760.09 [52]. - The company completed the acquisition of 100% equity in Chuangfa Enterprises, indirectly holding 45% of Dongguan Guangming Eye Hospital, which achieved revenue of CNY 213,144,178.60, up 18.40% year-on-year [37]. - The company plans to continue expanding its market presence through strategic acquisitions and investments in the healthcare sector [52]. Research and Development - The number of R&D personnel grew by 90.00%, reflecting the company's commitment to enhancing medical technology investments [22]. - The company’s R&D investment amounted to ¥11,033,602.57 in 2023, representing 0.41% of operating revenue, an increase from 0.39% in 2022 [132]. - The company published 31 academic papers in SCI and Medicine, obtained 9 patents, and initiated 11 provincial, municipal, and district-level research projects in 2023 [108]. - The company has a research personnel ratio of 1.55% in 2023, up from 1.01% in 2022, indicating a focus on enhancing research capabilities [110]. Operational Strategy - The company aims to strengthen its technical capabilities and provide comprehensive eye health solutions for all age groups [34]. - The company operates under a "direct chain" business model, focusing on providing comprehensive ophthalmic medical services including refractive surgery, cataract treatment, and medical optometry [102]. - The company has implemented talent development programs, including the "Eagle Plan" for management training, to enhance its workforce capabilities [34]. - The company is focused on maintaining a stable financial position with no significant changes in shareholding among its directors and supervisors [151]. Market Expansion - The company has opened 27 chain ophthalmology specialty hospitals, covering all municipalities and over ten provincial capital cities, enhancing its national chain strategy [34]. - The company is expanding its presence in major cities, with new hospitals in cities like Kunming, Urumqi, and Shenzhen under construction [37]. - The company is focusing on expanding its market presence and enhancing its brand through strategic acquisitions and partnerships in the ophthalmic sector [95]. - The company aims to enhance eye health services in line with national health initiatives, targeting a 90% coverage rate for annual eye health checks for children aged 0-6 by 2025 [97]. Cash Flow and Dividends - The company distributed a cash dividend of CNY 4.00 per 10 shares, totaling CNY 596,000,000 [5]. - The net cash flow from operating activities reached ¥614,461,445.75, a significant increase of 92.44% compared to the previous year [137]. - The company plans to distribute cash dividends of no less than 10% of the distributable profits for the year, contingent on achieving profitability [164]. - The cash dividend per 10 shares for the current year was RMB 4.00, with a total cash dividend amount of RMB 59,545,512.40 [168]. Compliance and Governance - The company has a clear governance structure with independent directors and supervisors in place, ensuring compliance and oversight [151]. - The company has not reported any changes in the board of directors or senior management during the reporting period [153]. - The company has not engaged in any securities or derivative investments during the reporting period [68][69]. - The company was recognized for its ESG governance, receiving multiple awards including "2023 ESG Excellent Practice Case" from the China Listed Companies Association [108].

证券代码：301239 证券简称：普瑞眼科 公告编号：2024-016 成都普瑞眼科医院股份有限公司 关于会计政策变更的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 成都普瑞眼科医院股份有限公司（以下简称"公司"）本次会计政策变更 系根据中华人民共和国财政部（以下简称"财政部"）颁布的《企业会计准则 解释第16号》（财会〔2022〕31号，以下简称"解释16号"）、《企业会计准 则解释第17号》（财会〔2023〕21号，以下简称"解释17号"）的要求变更会 计政策，无需提交董事会和股东大会审议，对公司当期财务报表无影响，不涉 及以前年度的追溯调整，不存在损害公司及股东利益的情形。 一、会计政策变更概述 （一）变更原因及日期 1．2022年11月30日，财政部颁布《企业会计准则解释第16号》（财会 〔2022〕31号），其中"关于单项交易产生的资产和负债相关的递延所得税不 适用初始确认豁免的会计处理"的内容自2023年1月1日起施行。 公司根据上述会计准则解释规定，对会计政策进行相应变更，并按以上文 件规定的生效日期开始执行上述会计准则。该项 ...

成都普瑞眼科医院股份有限公司 董事会议事规则 第一章 总则 第一条 为了保护公司和股东的合法权益，规范董事的行为，理顺公司管理 体制，明晰董事会的职责权限，建立规范化的董事会组织架构及运作程序，保 障公司经营决策高效、有序地进行，依照《中华人民共和国公司法》《中华人民 共和国证券法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市 公司自律监管指引第 2 号——创业板上市公司规范运作》等其他规范性文件以 及《成都普瑞眼科医院股份有限公司章程》（以下简称"公司章程"）的规定， 制定本规则。 董事会秘书应遵守法律、行政法规、部门规章、规范性文件及公司章程、 公司董事会秘书工作细则的有关规定。 第五条 董事会下设董事会办公室，处理董事会日常事务。 1 第二章 董事会的组成和组织机构 第二条 公司依法设立董事会，董事会是公司的常设机构，是公司经营决策 机构，行使法律法规以及公司章程规定的职权，对股东大会负责并向其报告工 作。 第三条 公司董事会由 7 名董事组成，其中独立董事 3 名。公司独立董事占 董事会成员的比例不得低于三分之一，且至少包括一名会计专业人士。公司设 董事长一人，由董事会以全体董事的过半数选 ...

成都普瑞眼科医院股份有限公司 独立董事工作细则 第一章 总则 第一条 为了促进公司的规范运作，维护公司整体利益，保障全体股东特别 是中小股东的合法权益不受损害，根据《中华人民共和国公司法》（以下称"《公 司法》"）、《中华人民共和国证券法》《深圳证券交易所创业板股票上市规则》 《上市公司独立董事管理办法》（以下称"《独立董事管理办法》"）《深圳证 券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》《上市公 司治理准则》等法律、行政法规、规范性文件和《成都普瑞眼科医院股份有限公 司章程》（以下称"《公司章程》"）的有关规定，制定本细则。 第二条 独立董事是指不在本公司担任除董事外的其他职务，并与公司及其 主要股东、实际控制人不存在直接或者间接利害关系，或者其他可能影响其进行 独立客观判断关系的董事。 第三条 独立董事对公司及全体股东负有忠实与勤勉义务，应当按照法律、 行政法规、中国证券监督管理委员会（以下称"中国证监会"）规定、证券交易 所业务规则和公司章程的规定，认真履行职责，在董事会中发挥参与决策、监督 制衡、专业咨询作用，维护上市公司整体利益，保护中小股东合法权益。 第四条 独立董事应当持 ...

Financial Performance - The company's operating revenue for Q1 2024 was ¥675,882,973.16, representing a 4.01% increase compared to ¥649,826,753.50 in the same period last year[40]. - The net profit attributable to shareholders of the listed company decreased by 89.58% to ¥16,924,936.43 from ¥162,393,315.01 year-on-year[40]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥19,084,077.60, down 73.28% from ¥71,427,627.21 in the previous year[40]. - The basic and diluted earnings per share both dropped to ¥0.11, a decline of 89.91% from ¥1.09 in the same period last year[40]. - The total comprehensive income attributable to the parent company's shareholders was significantly impacted, with a net profit of ¥16,924,936.43 compared to ¥162,393,315.01 previously, a decrease of approximately 89.6%[50]. - The operating profit for the current period was ¥41,355,597.39, down from ¥191,474,382.80, reflecting a decline of about 78.4%[50]. Cash Flow and Investments - The net cash flow from investment activities for the first quarter of 2024 was -¥196,363,723.78, a 63.02% increase in outflow compared to the same period last year[5]. - The net cash flow from operating activities was ¥125,706,825.28, an increase of 4.37% compared to ¥120,447,583.12 in the same period last year[40]. - Cash inflow from operating activities totaled ¥679,993,838.41, up from ¥618,035,398.46, reflecting an increase of around 10.0%[67]. - Cash outflow from operating activities was ¥554,287,013.13, compared to ¥497,587,815.34, which is an increase of about 11.4%[67]. - The company reported a significant decrease in investment income, down 99.37% to ¥583,182.02, due to revaluation of equity in a previously acquired hospital[5]. Assets and Liabilities - The total assets at the end of the reporting period were ¥4,739,576,891.70, a decrease of 1.57% from ¥4,815,000,387.93 at the end of the previous year[40]. - The total liabilities decreased from ¥2,496,787,457.87 to ¥2,432,122,786.09, a reduction of approximately 2.6%[49]. - The total equity attributable to shareholders decreased from ¥2,291,622,601.45 to ¥2,278,746,073.33, a decrease of approximately 0.6%[49]. - Current liabilities decreased to ¥774,628,304.72 from ¥1,043,136,742.01, a reduction of approximately 25.7%[62]. - Non-current assets totaled ¥3,564,118,373.11, down from ¥3,600,194,099.58, indicating a decrease of about 1.0%[62]. Borrowings and Financial Expenses - The company's short-term borrowings decreased by 57.77% to ¥98,428,416.67, resulting from repayments made during the period[5]. - The company's long-term borrowings increased by 206.71% to ¥290,778,074.66, reflecting new loans taken from banks during the period[5]. - Financial expenses increased by 40.33% to ¥18,121,370.70, mainly due to higher interest expenses from leasing new hospital properties[5]. Other Financial Metrics - The company's prepaid expenses increased by 203.24% to ¥29,497,219.69, primarily due to increased procurement payments for newly opened hospitals[5]. - The company's contract liabilities rose by 30.68% to ¥20,706,725.05, driven by growth in optical business and increased prepayments for eyewear[5]. - The company experienced a 104.89% increase in taxes and surcharges, totaling ¥1,261,475.64, mainly due to property tax and stamp duty from new properties[5]. - The company recorded a government subsidy of ¥1,027,746.09 during the reporting period[55]. - The weighted average return on net assets was 0.74%, a decrease of 6.82% from 7.56% in the same period last year[40]. - The company has maintained its capital reserve at approximately ¥1,735,326,760.56, showing stability in this area[49]. Share Repurchase - The company continued its stock repurchase program, resulting in a 99.40% increase in treasury shares to ¥59,770,175.60[5]. - The company repurchased a total of 755,267 shares, accounting for 0.50% of the total share capital, with a total transaction amount of ¥59,770,175.60[47].

成都普瑞眼科医院股份有限公司 独立董事2023年度述职报告 （陈凌云） 2023年度，本人作为成都普瑞眼科医院股份有限公司（以下简称"公司"） 第三届董事会独立董事，严格按照《中华人民共和国公司法》（以下简称 "《公司法》"）《上市公司独立董事管理办法》《深圳证券交易所创业板股 票上市规则》《深圳证券交易所上市公司自律监管指引第2号——创业板上市公 司规范运作》等法律法规及《公司章程》《独立董事工作细则》等公司相关规 定和要求，本着严谨认真、勤勉尽责、诚实独立的原则，通过积极参加董事会 和股东大会谨慎审核公司提交的各项议案，对公司重大事项发表独立意见以及 发挥董事会专门委员会的作用等方式忠实履行了独立董事的职责和义务，切实 维护了公司整体利益和全体股东的合法权益。现将本人2023年度工作情况汇报 如下： 一、基本情况 （一）工作履历、专业背景以及兼职情况 本人陈凌云，1979年出生,中国国籍,无境外永久居留权,2006年6月获厦门 大学管理学(会计学)博士学位；现为东华大学管理学院副教授,硕士生导师,工 商管理系副主任,会计专业硕士学位点学术负责人。主要研究领域包括会计准则、 内部控制与风险管理、审计等。在《 ...

成都普瑞眼科医院股份有限公司 董事会审计委员会工作细则 第一章 总 则 第一条 为强化董事会决策功能，做到事前审计、专业审计，确保董事会对 经理层的有效监督，完善公司治理结构，根据《中华人民共和国公司法》、《上市 公司治理准则》、《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市 公司规范运作》、《成都普瑞眼科医院股份有限公司章程》（以下称"《公司章程》"） 及其他有关规定，依据公司股东大会的相关决议，公司特设立董事会审计委员会， 并制定本工作细则。 第五条 审计委员会设主任委员（召集人）一名，由独立董事委员担任，且 该召集人应当为会计专业人士，负责主持委员会工作；主任委员在委员内选举产 生。 第六条 审计委员会任期与董事会任期一致，委员任期届满，连选可以连任。 期间如有委员不再担任公司董事职务，自动失去委员资格，并由董事会根据上述 第三条至第五条的规定补足委员人数。 第四条 审计委员会委员由董事长、二分之一以上独立董事或全体董事三分 之一以上（包括三分之一）提名，并由董事会选举产生。 选举委员的提案获得通过后，新任委员在董事会会议结束后立即就任。 第七条 审计委员会日常工作的联络、会议组织和决议落 ...

上市公司独立董事候选人声明与承诺 声明人邹欢作为成都普瑞眼科医院股份有限公司第三届董事会独立董事 候选人，已充分了解并同意由提名人成都普瑞眼科医院股份有限公司董事会提 名为成都普瑞眼科医院股份有限公司（以下简称该公司）第三届董事会独立董 事候选人。现公开声明和保证，本人与该公司之间不存在任何影响本人独立性 的关系，且符合相关法律、行政法规、部门规章、规范性文件和深圳证券交易 所业务规则对独立董事候选人任职资格及独立性的要求，具体声明并承诺如下 事项： 一、本人已经通过成都普瑞眼科医院股份有限公司第三届董事会提名委员 会或者独立董事专门会议资格审查，提名人与本人不存在利害关系或者其他可 能影响独立履职情形的密切关系。 是 □ 否 如否，请详细说明：_____________________________ 二、本人不存在《中华人民共和国公司法》第一百四十六条等规定不得担 任公司董事的情形。 是 □ 否 如否，请详细说明：______________________________ 三、本人符合中国证监会《上市公司独立董事管理办法》和深圳证券交易 所业务规则规定的独立董事任职资格和条件。 是 □ 否 如否，请详细 ...

证券代码：301239 证券简称：普瑞眼科 公告编号：2024-018 成都普瑞眼科医院股份有限公司 关于调整超募资金投资项目实施进度的公告 按规定存放于公司募集资金专户。 二、募集资金投资项目情况 截至本公告披露日，公司首次公开发行股票募集资金投资项目及募集资金 使用计划如下： | 序号 | 项目名称 | 项目投资总额 | 拟投入募集资金金额 | | --- | --- | --- | --- | | | | （元） | （元） | | | 募集资金投资项目/使用计划 | | | | 1 | 长春普瑞眼科医院新建项目 | 74,204,500.00 | 74,204,500.00 | | 2 | 哈尔滨普瑞眼科医院改建项目 | 30,413,300.00 | 30,413,300.00 | | 3 | 信息化管理建设项目 | 101,593,600.00 | 101,593,600.00 | | 4 | 补充流动资金项目 | 80,000,000.00 | 80,000,000.00 | | | 超募资金投资项目/使用计划 | | | | 5 | 湖北普瑞眼科医院新建项目 | 100,000,000.00 ...